Evogene (EVGN) announced a collaboration with Google Cloud (GOOG, GOOGL) to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small molecules. This groundbreaking initiative seeks to advance the discovery and development of novel small molecules for drug development, sustainable crop protection, and other innovative products across a wide range of life-science industries.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVGN:
- Evogene receives grant from IIA to advance development of ‘MicroFermentor’
- Evogene files to sell 3.38M ordinary shares for holders
- Evogene Announces Major Management Restructuring
- Evogene Ltd. Reports Mid-Year Financial Dip
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
